Last reviewed · How we verify
Another Available A1PI
This drug replaces deficient alpha-1 protease inhibitor (A1PI) protein to prevent progressive lung damage in patients with alpha-1 antitrypsin deficiency.
This drug replaces deficient alpha-1 protease inhibitor (A1PI) protein to prevent progressive lung damage in patients with alpha-1 antitrypsin deficiency. Used for Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease.
At a glance
| Generic name | Another Available A1PI |
|---|---|
| Also known as | Alpha1-PI, Alpha1-Proteinase Inhibitor (Human) |
| Sponsor | Takeda |
| Drug class | Protease inhibitor replacement therapy |
| Target | Alpha-1 protease inhibitor (A1PI) |
| Modality | Biologic |
| Therapeutic area | Pulmonology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
Alpha-1 antitrypsin is a protease inhibitor that protects lung tissue from degradation by neutrophil elastase. In alpha-1 antitrypsin deficiency, insufficient levels of this protective protein lead to unopposed elastase activity and progressive emphysema. Intravenous A1PI augmentation therapy restores circulating and lung levels of the inhibitor, slowing or halting lung function decline.
Approved indications
- Alpha-1 antitrypsin deficiency with emphysema or chronic obstructive pulmonary disease
Common side effects
- Infusion-related reactions
- Headache
- Fatigue
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Another Available A1PI CI brief — competitive landscape report
- Another Available A1PI updates RSS · CI watch RSS
- Takeda portfolio CI